Sculptra vs Radiesse: How They Differ, How Long They Take and What Studies Show

Start with our pillar guide: Argireline vs Matrixyl: Mechanisms, Trials and Which to Use, or browse all Reviews & Comparisons articles.

Sculptra vs Radiesse comes down to timing and material: Sculptra (poly-L-lactic acid) builds volume gradually, while Radiesse (calcium hydroxylapatite) adds volume immediately and also stimulates collagen. No clinical trial in our review compares their results head to head, and neither can be reliably dissolved like hyaluronic acid filler. Evidence: Limited.

Both are "biostimulators," injectables meant to prompt your skin to make new collagen. This page covers which injectable fits which goal, based on what the studies actually measured. It also flags which "Sculptra" studies used Sculptra and which used other PLLA brands. If your volume loss followed GLP-1 weight loss, our review of dermal fillers for Ozempic face goes deeper. For non-injectable options, see peptides for skin tightening, which sit in a much weaker evidence tier.

Key takeaways

• The only direct Sculptra vs Radiesse comparison is gene expression: two reports from one group, possibly the same 21 people, found PLLA leaned toward tissue-building genes and CaHA toward inflammatory genes (Waibel et al., 2024; Waibel et al., 2025).
• In a 208-person randomized trial, a PLLA filler matched hyaluronic acid (HA) filler at 4 and 12 weeks, and by 120 weeks 55.56% vs 25.00% still had effective correction (Liu et al., 2026). The abstract doesn't name the PLLA brand.
• Radiesse is calcium hydroxylapatite (CaHA) microspheres in a carboxymethylcellulose gel and gives immediate volume, according to a narrative review (Aguilera et al., 2023).
• In 55 Brazilian biostimulator complication cases, hyaluronidase helped only when HA was also present, and only 5 cases fully resolved (Ianhez et al., 2024).
• We didn't find a Radiesse duration figure in the studies we reviewed.

What's the difference between Sculptra and Radiesse?

Sculptra is poly-L-lactic acid microparticles that trigger slow collagen growth, while Radiesse is calcium hydroxylapatite microspheres in a gel that fill right away and then stimulate collagen. The practical difference is how fast you see volume.

Sculptra (PLLA-SCA) was approved in 1999 in Europe and 2004 in the US as a collagen biostimulator. It's a freeze-dried powder with 150 mg of PLLA per vial (Vasconcelos-Berg et al., 2024). A review describes PLLA as prompting a "subclinical inflammatory response," meaning a low-level reaction you can't see, that leads to collagen deposition (Fitzgerald et al., 2018).

Radiesse, made by Merz Aesthetics, suspends CaHA microspheres in a carboxymethylcellulose (CMC) gel, a thickener that carries the particles. A narrative review reports immediate volumization plus increases in collagen, elastin and blood vessels (Aguilera et al., 2023).

Evidence: Limited (mostly narrative reviews).

What do head-to-head Sculptra vs Radiesse studies show?

The only direct Sculptra vs Radiesse data measure gene activity in skin biopsies, not how faces looked. No study in our review compares their clinical results.

Waibel and colleagues ran a randomized, 13-week study in 21 people, injecting PLLA-SCA (Sculptra) and CaHA-R (Radiesse) into the nasolabial folds (the lines from nose to mouth corner). Biopsies at baseline and Day 90 showed different gene regulation for 9 to 12 genes (p < .05). Only PLLA linked to genes involved in fat-cell regeneration. The authors wrote that this "could translate" to healthier fat replacement, which is a hypothesis, not a measured result (Waibel et al., 2024).

A second report from the same group, also randomized with 21 people over 13 weeks, found PLLA stimulated more extracellular matrix (the skin's structural scaffolding) with less inflammation. CaHA "did not show evidence of tissue regeneration" (Waibel et al., 2025). These may be the same 21 people, so treat them as one small study. Funding isn't reported in either abstract.

Reviews add context but not clinical proof. A 2026 review of 22 studies says CaHA shows a stronger early inflammatory signature than PLLA (Flores Rodríguez et al., 2026). Another notes HA filler is biostimulatory too, and that research comparing new collagen formation across fillers is scarce (Haddad et al., 2022).

Evidence: Early / preliminary (one small biopsy study, no clinical outcomes).

How long does Sculptra take to work?

Sculptra-type PLLA works gradually, with volume still rising months after treatment. In trials, PLLA matched HA filler in the first 12 weeks and pulled ahead later.

Byun and colleagues ran a split-face, evaluator-blind randomized trial in 24 volunteers over 12 months. Measured cheek volume rose from +2.12 cc at 1 month to +3.17 cc at 12 months on one side, and from +2.26 cc to +3.19 cc on the other (Byun et al., 2015; non-US government research support; product brand not named in the abstract).

In the Liu trial, effective correction was similar for PLLA and HA at 4 weeks (89.80% vs 92.78%) and 12 weeks (90.00% vs 88.12%), then favored PLLA at 24, 36 and 52 weeks (Liu et al., 2026). A placebo-controlled trial of 10 women measured improvement 18 weeks after the last of 3 sessions (Arruda et al., 2024).

The early swelling many people notice right after a PLLA session is clinic convention; no study in our review measures it. Any "results in X weeks" promise is also clinic convention.

Evidence: Limited (PLLA brands in these trials are not named as Sculptra).

How fast does Radiesse work, and what is hyperdilute Radiesse?

Standard Radiesse adds volume immediately, per reviews. Hyperdilute Radiesse is diluted to spread thinly and trades that instant volume for gradual collagen stimulation.

A Merz-consultant review says hyperdilution reduces the immediate volume effect and emphasizes new collagen and elastin over larger areas (Soza, 2026). In the studies we found, CaHA-CMC was diluted at a 1:3 ratio.

• Perioral pilot: 12 women had 1:3 hyperdilute CaHA at weeks 1 and 8, then HA filler at week 16. 83% improved at least 1 wrinkle grade (P = .0156). Because HA was added, the study can't isolate the CaHA effect. The author is a consultant, investigator and speaker for Galderma and Merz (Somenek, 2024).
• Chart review: 22 patients had 2 sessions at 1:3. By Day 150, cheek volume rose (P = .0012) and jowl volume, nasolabial fold depth and marionette line depth fell. Aesthetic ratings peaked at Day 150 (Durairaj et al., 2025; funding not stated in the abstract).
• Order pilot: In a randomized pilot of 12 women, microfocused ultrasound followed by hyperdilute CaHA 6 weeks later raised elastin coverage 143% vs 63% for the reverse order at 120 days (Doyle et al., 2025).

No study compares hyperdilute Radiesse with Sculptra.

Evidence: Early / preliminary.

How many sessions do Sculptra and Radiesse need?

Studies used 2 to 3 PLLA sessions and 2 hyperdilute CaHA sessions, and splitting the same PLLA dose into 2 or 3 visits made no measurable difference.

In the Byun trial, one cheek got 3 injections of 4 cc and the other 2 injections of 6 cc. Results didn't differ (Byun et al., 2015). The Arruda trial used 3 sessions 4 weeks apart (Arruda et al., 2024). In a retrospective review of 167 Sculptra patients, people had 1 to 5 sessions each (Vasconcelos-Berg et al., 2024).

The hyperdilute CaHA studies above used 2 sessions. Beyond these protocols, typical session counts and intervals are clinic convention.

Evidence: Early / preliminary.

How long does Sculptra vs Radiesse last?

For PLLA, one randomized trial tracked results to 120 weeks. We didn't find a Radiesse duration figure in the studies we reviewed.

In the Liu trial, 55.56% (35/63) of PLLA patients vs 25.00% (18/72) of HA patients still had effective correction at 120 weeks (P < 0.001). The authors say these extension data should be read in light of attrition: only 135 of the original 208 were analyzed (Liu et al., 2026; no conflicts reported).

A systematic review of 11 PLLA trials found effects sustained for at least 25 months in 4 studies. It rated the evidence "low quality," with 5 of 11 trials at high risk of bias, and 2 authors are Galderma speakers (Signori et al., 2024).

For comparison, a review reports that polycaprolactone (PCL), another biostimulator class, produces collagen growth lasting up to 24 months (Flores Rodríguez et al., 2026).

Evidence: Limited.

Sculptra vs HA filler: which is better for volume?

HA filler gives immediate volume and can be partly reversed, while PLLA builds slowly and lasted longer in two randomized trials. Neither trial named Sculptra or a specific HA brand such as Juvéderm, Restylane or Voluma.

A review summarizes the trade-off: HA "provides immediate volume" but needs crosslinking for durability, while PLLA and PCL stimulate collagen for longer-lasting effects (Liu et al., 2025; no conflicts declared).

• Midface: A 331-person multicenter, assessor-blinded RCT found PLLA beat HA on the primary midface volume endpoint, 90.57% vs 51.01%. The full text defines that endpoint at 12 months after the last injection. Secondary 12-month figures were 84.91% vs 46.98%. Injection-site reactions were slightly more common with PLLA and resolved in 1 to 3 days (Zhang et al., 2025; authors declare no conflicts).
• Nasolabial folds: The Liu trial above found no difference through 12 weeks and an advantage for PLLA afterward.
• Different product: A 260-person RCT of AestheFill, a poly-D,L-lactic acid (PDLLA) filler and not Sculptra, found 67.6% vs 60.9% improved at 24 weeks vs HA (Ting et al., 2024).

One trial cuts the other way. In a 55-person split-face RCT in France, a 6-month interim report, Sculptra's nasolabial fold improvement was not statistically significant (mean difference −0.20; 95% CI −0.42 to 0.03). Sculptra was the comparator, and the new PLLA filler Gana V was judged non-inferior (p = 0.1787 for non-inferiority) (Han et al., 2023; funding not reported in the abstract). That is a small, early, single-area result.

Evidence: Limited.

Sculptra vs Radiesse side effects: do they cause lumps?

Nodules, or small firm lumps under the skin, are the best-known risk for both, and reported rates vary widely. Rare but serious risks shared by facial fillers include vascular occlusion and blindness.

• A 2026 review reports PLLA nodule rates of 4.7% to 28.6% (Flores Rodríguez et al., 2026).
• In 167 patients treated with immediately reconstituted Sculptra, 1 developed a nodule, which resolved after 2 saline injections. Facial bruising occurred in 6.57% of cases. Three authors received Galderma speaker fees (Vasconcelos-Berg et al., 2024).
• In an uncontrolled study of 52 women given Elleva, a different PLLA product, 1 small nodule resolved on its own (Bravo et al., 2025; several authors had Rennova ties).
• A systematic review of 29 combination studies reported erythema, bruising and nodules in 15% to 30% of cases, with rare granulomas and vascular occlusions (Tam et al., 2025).
• A filler review lists vascular occlusion, nodules and blindness among severe complications (Liu et al., 2025).

The 55 Brazilian complication cases came from Elleva (49.1%), CaHA alone or with HA (23.6%), Sculptra (20.0%) and PCL (7.3%). Most were on the face (72.7%), 89.1% were nodules, and 60.0% appeared more than 1 month after treatment (Ianhez et al., 2024). These are complication cases, so they can't show how often lumps happen.

Evidence: Limited.

Can Sculptra or Radiesse be dissolved like HA filler?

No reliable reversal exists for either in the studies we reviewed. HA filler is different: hyaluronidase, an enzyme that breaks down HA, can reduce it.

A review of under-eye filler complications says hyaluronidase injection "generally is effective" in reducing overcorrection or migration of HA gel (Wang et al., 2021). In the 55 biostimulator complication cases, treatments included saline, hyaluronidase, diluted corticosteroids and energy devices, yet only 5 cases fully resolved. Hyaluronidase helped only when CaHA had been combined with HA (p < 0.01) (Ianhez et al., 2024).

Evidence: Limited.

Sculptra vs Radiesse for the buttocks, body or GLP-1 volume loss?

No study compares Sculptra and Radiesse on the buttocks or body. Evidence for each is thin and mostly technique-based.

Buttocks and body

The hyperdilute Radiesse glute evidence is a technical report describing a patented technique, with no outcome data. Its first author provides private training in the method (Silveira and Martinez, 2022). A review mentions hyperdilute CaHA for the glutes, arms and abdomen (Soza, 2026). On the PLLA side, the 167-patient Sculptra series included 39 body sessions in 22 patients without naming sites (Vasconcelos-Berg et al., 2024). For skin that sagged after weight loss, see loose skin after weight loss. For aging hands, including which fillers have hand approvals, see our guide to hand rejuvenation.

Facial volume loss on a GLP-1

A case series of 4 GLP-1 users found facial measurements stayed stable or improved after hyperdilute Radiesse despite losing 9.2% of body weight on average over 6 months (Durairaj et al., 2025). A PLLA systematic review lists post-GLP-1 restoration as a use (Haykal et al., 2025), and a commentary flags gaps in data and timing (Haykal et al., 2025). Our pages on fixing Ozempic face and fillers for Ozempic face cover this in depth. Any medication question belongs with your prescriber.

Evidence: Early / preliminary.

Sculptra vs Radiesse cost: what drives the price?

We found no sourced Sculptra vs Radiesse cost figures, so we don't publish price ranges. The main cost drivers are the number of vials or syringes and the number of sessions, which is clinic convention rather than study data.

Because PLLA protocols in trials used 2 to 3 sessions and hyperdilute CaHA used 2, total cost depends on the full plan, not one visit. One technical report calls biostimulators "relatively low cost," but that is the authors' statement, not a measured comparison (Silveira and Martinez, 2022). Ask for an itemized quote that includes likely follow-up sessions.

What does Sculptra aftercare involve?

Follow your injector's written instructions. Massage routines such as the "5-5-5" rule and set day counts are clinic convention or manufacturer guidance; no study in our review tests them.

One sourced detail affects preparation, not aftercare: since 2021 the manufacturer has authorized reconstituting Sculptra immediately before use instead of 72 hours ahead. In 167 patients, the adverse event profile was similar to the older method (Vasconcelos-Berg et al., 2024). For which general post-injection skincare rules have evidence, see skincare after Botox and what not to do after lip filler. If you're wondering whether a supplement can do the same job, our collagen supplements review covers that separate evidence.

Evidence: Limited. No study tests aftercare regimens; this is clinic convention.

Where the evidence stops

• No head-to-head clinical trial compares Sculptra and Radiesse outcomes.
• Long-term PLLA trials don't name Sculptra. The trial that does name it reported a non-significant Sculptra result at a 6-month interim.
• No Radiesse duration figure appeared in the studies we reviewed.
• Hyperdilute CaHA evidence comes from pilots and chart reviews of 22 people or fewer, several with Merz or Galderma ties.
• Aftercare, costs and session counts are clinic convention.
• Fat regeneration with PLLA is a gene-expression hypothesis, not a clinical finding.

FAQ

References

1. Waibel J, et al. Comparative Bulk RNA-Seq Analysis of Poly-l-Lactic Acid Versus Calcium Hydroxylapatite Reveals a Novel, Adipocyte-Mediated Regenerative Mechanism of Action Unique to PLLA. Dermatol Surg. 2024. Randomized, n=21, 13 weeks; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/39480040/
2. Waibel J, et al. Gene Analysis of Biostimulators: Poly-L-Lactic Acid Triggers Regeneration While Calcium Hydroxylapatite Induces Inflammation Upon Facial Injection. J Drugs Dermatol. 2025. Randomized, n=21, 13 weeks; possibly same cohort as ref 1; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/39761144/
3. Flores Rodríguez JC, et al. Mechanisms of Cytokine Modulation and Inflammatory Cascade in Bio-stimulatory Skin Rejuvenation: A Comprehensive Literature Review of Poly-L-Lactic Acid, Calcium Hydroxyapatite, Polycaprolactone, and Poly-D, L-Lactic Acid. Cureus. 2026. Narrative review, 22 studies; no financial support declared. https://pubmed.ncbi.nlm.nih.gov/42211639/
4. Haddad S, et al. Evaluation of the biostimulatory effects and the level of neocollagenesis of dermal fillers: a review. Int J Dermatol. 2022. Review. https://pubmed.ncbi.nlm.nih.gov/35486036/
5. Fitzgerald R, et al. Physiochemical Characteristics of Poly-L-Lactic Acid (PLLA). Aesthet Surg J. 2018. Review. https://pubmed.ncbi.nlm.nih.gov/29897517/
6. Aguilera SB, et al. The Role of Calcium Hydroxylapatite (Radiesse) as a Regenerative Aesthetic Treatment: A Narrative Review. Aesthet Surg J. 2023. Narrative review. https://pubmed.ncbi.nlm.nih.gov/37635437/
7. Liu J, et al. Facial Injectable Fillers in Aesthetic Medicine: Clinical Applications and Safety Strategies. Med Sci Monit. 2025. Review; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/41199535/
8. Liu Y, et al. Divergent Time Courses of Poly-L-Lactic Acid and Hyaluronic Acid Fillers for Nasolabial Fold Correction: A Multicenter Randomized Trial With 120-Week Follow-Up. J Craniofac Surg. 2026. RCT n=208, 135 analyzed at 120 weeks; PLLA brand not stated; no conflicts reported. https://pubmed.ncbi.nlm.nih.gov/42594306/
9. Zhang Y, et al. Efficacy and Safety of Poly-l-Lactic Acid for Correction of Midfacial Volume Loss and Contour Defects: A Prospective, Multicenter, Randomized, Parallel-Controlled, Evaluator-Blinded, Superiority Trial. J Cosmet Dermatol. 2025. Multicenter RCT n=331, 12 months; PLLA brand not stated; no conflicts declared. https://pubmed.ncbi.nlm.nih.gov/40679154/
10. Byun SY, et al. Objective Analysis of Poly-L-Lactic Acid Injection Efficacy in Different Settings. Dermatol Surg. 2015. Split-face RCT n=24, 12 months; non-US government support. https://pubmed.ncbi.nlm.nih.gov/26618458/
11. Arruda S, et al. A Clinical Histology Study Evaluating the Biostimulatory Activity Longevity of Injectable Poly-L-Lactic Acid for Facial Rejuvenation. J Drugs Dermatol. 2024. Placebo-controlled RCT n=10, follow-up 18 weeks after last session; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/39231078/
12. Signori R, et al. Efficacy and Safety of Poly-l-Lactic Acid in Facial Aesthetics: A Systematic Review. Polymers (Basel). 2024. Systematic review, 11 RCTs; 2 authors Galderma speakers. https://pubmed.ncbi.nlm.nih.gov/39339028/
13. Han WY, et al. Safety and Efficacy of Poly-L-Lactic Acid Filler (Gana V vs. Sculptra) Injection for Correction of the Nasolabial Fold: A Double-Blind, Non-Inferiority, Randomized, Split-Face Controlled Trial. Aesthetic Plast Surg. 2023. Split-face RCT n=55, 6-month interim; NCT05215054; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/37626137/
14. Ting W, et al. A Randomized, Evaluator-Blinded, Multicenter Study to Compare Injectable Poly-D,L-Lactic Acid vs Hyaluronic Acid for Nasolabial Fold Augmentation. Aesthet Surg J. 2024. RCT n=260, 52 weeks; AestheFill (PDLLA), not Sculptra. https://pubmed.ncbi.nlm.nih.gov/39178357/
15. Bravo BSF, et al. Exploring the Safety and Satisfaction of Patients Injected With Collagen Biostimulators-A Prospective Investigation Into Injectable Poly-l-Lactic Acid (PLLA). J Cosmet Dermatol. 2025. Uncontrolled prospective n=52, 150 days; Elleva PLLA, not Sculptra; Rennova speaker ties. https://pubmed.ncbi.nlm.nih.gov/39663956/
16. Haykal D, et al. Poly-L-Lactic Acid in Aesthetic Dermatology: A Decade Beyond Volume Restoration Toward Regenerative Biostimulation. Aesthet Surg J. 2025. Systematic review, 63 studies. https://pubmed.ncbi.nlm.nih.gov/40580932/
17. Soza GM. Hyperdilute Calcium Hydroxylapatite for Skin Quality and Contour: Clinical Applications, Technique, and Practical Considerations. Dermatol Clin. 2026. Review; author is a Merz consultant. https://pubmed.ncbi.nlm.nih.gov/42303355/
18. Somenek M. Hyperdilute Calcium Hydroxylapatite for the Treatment of Perioral Rhytids: A Pilot Study. Aesthet Surg J Open Forum. 2024. Pilot n=12, confounded by HA at week 16; author consultant, investigator and speaker for Galderma and Merz. https://pubmed.ncbi.nlm.nih.gov/38660236/
19. Durairaj KK, et al. Sculpting the Midface and Lower Face: A Novel Biostimulatory Technique Using Hyperdilute Calcium Hydroxylapatite. Aesthet Surg J Open Forum. 2025. Chart review n=22, Day 150; funding not stated in abstract. https://pubmed.ncbi.nlm.nih.gov/41376672/
20. Doyle A, et al. Microfocused Ultrasound With Visualization (MFU-V) and Hyperdilute Calcium Hydroxylapatite (CaHA-CMC) of the Lower Face and Submentum to Treat Skin Laxity: A Pilot Study Demonstrating Superiority of MFU-V First Followed by Hyperdilute CaHA-CMC. Aesthet Surg J. 2025. Randomized pilot n=12, 120 days; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/39511699/
21. Silveira I, Martinez B. Bilateral Gluteal Augmentation With Hyperdilute Calcium Hydroxylapatite Microspheres Performed Using the Bella Vida Instant Brazilian Butt Lift (BBL)™. Cureus. 2022. Technical report, no outcome data; patent holder, first author provides private training. https://pubmed.ncbi.nlm.nih.gov/35911363/
22. Ianhez M, et al. Complications of collagen biostimulators in Brazil: Description of products, treatments, and evolution of 55 cases. J Cosmet Dermatol. 2024. Case series from expert questionnaire, 55 cases. https://pubmed.ncbi.nlm.nih.gov/38693639/
23. Vasconcelos-Berg R, et al. Safety of the Immediate Reconstitution of Poly-l-Lactic Acid for Facial and Body Treatment-A Multicenter Retrospective Study. J Cosmet Dermatol. 2024. Retrospective, 167 patients, 274 sessions; 3 authors received Galderma speaker fees. https://pubmed.ncbi.nlm.nih.gov/39285829/
24. Tam E, et al. A Systematic Review on the Effectiveness and Safety of Combining Biostimulators with Botulinum Toxin, Dermal Fillers, and Energy-Based Devices. Aesthetic Plast Surg. 2025. Systematic review, 29 studies; authors have industry speaker and consultant ties. https://pubmed.ncbi.nlm.nih.gov/39719485/
25. Durairaj KK, et al. Hyperdilute Radiesse Preserves Facial Volume in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Rapid Weight Loss. Aesthet Surg J Open Forum. 2025. Retrospective case series n=4, 6 months. https://pubmed.ncbi.nlm.nih.gov/41127050/
26. Haykal D, et al. The Role of GLP-1 Agonists in Esthetic Medicine: Exploring the Impact of Semaglutide on Body Contouring and Skin Health. J Cosmet Dermatol. 2025. Commentary; authors report honoraria from multiple aesthetics companies including Galderma and Merz. https://pubmed.ncbi.nlm.nih.gov/39645647/
27. Wang Y, et al. Complications of Periocular Dermal Fillers. Facial Plast Surg Clin North Am. 2021. Review. https://pubmed.ncbi.nlm.nih.gov/33906766/

Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Brand names are trademarks of their owners. Biostimulators and fillers are medical procedures; ask a qualified, licensed injector about your options.

For educational purposes only; not medical advice. See our disclaimer and research method.